TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8

Lung Cancer

Volumn 60, Issue 3, 2008, Pages 355-365

  Belyanskaya, Larisa L ^a   Ziogas, Algirdas ^c   Hopkins Donaldson, Sally ^b   Kurtz, Stefanie ^b   Simon, Hans Uwe ^c   Stahel, Rolf ^b   Zangemeister Wittke, Uwe ^c  

^a SWISS FEDERAL LABORATORIES FOR MATERIALS SCIENCE AND TECHNOLOGY   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Caspase 8; Cell death proliferation; ERK1 2; IFN ; SCLC; TRAIL

Indexed keywords

CASPASE 8; DEATH RECEPTOR 5; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; GENE CONSTRUCT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CARCINOMA, SMALL CELL; CASPASE 8; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON TYPE II; LUNG NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION;

EID: 44249109720     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.11.005     Document Type: Article

References (45)

1. Travis W.D., Travis L.B., and Devesa S.S. Lung cancer. Cancer 75 (1995) 191-202
2. Brambilla E., Moro D., Gazzeri S., Brichon P.Y., Nagy-Mignotte H., Morel F., et al. Cytotoxic chemotherapy induces cell differentiation in small-cell lung carcinoma. J Clin Oncol 9 (1991) 50-61
3. Wistuba I.I., Gazdar A.F., and Minna J.D. Molecular genetics of small cell lung carcinoma. Semin Oncol 28 (2001) 3-13
4. Worden F.P., and Kalemkerian G.P. Therapeutic advances in small cell lung cancer. Expert Opin Investig Drugs 9 (2000) 565-579
5. Igney F.H., and Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2 (2002) 277-288
6. Johnstone R.W., Ruefli A.A., and Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
7. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5 (1999) 157-163
8. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104 (1999) 155-162
9. Corazza N., Brumatti G., Schaer C., Cima I., Wasem C., and Brunner T. TRAIL and immunity: more than a license to kill tumor cells. Cell Death Differ 11 Suppl 2 (2004) S122-S125
10. Ray S., and Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res 63 (2003) 4713-4723
11. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5 (2005) 876-885
12. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R., et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6 (2000) 564-567
13. Zamai L., Secchiero P., Pierpaoli S., Bassini A., Papa S., Alnemri E.S., et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 95 (2000) 3716-3724
14. Song K., Chen Y., Goke R., Wilmen A., Seidel C., Goke A., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 191 (2000) 1095-1104
15. Nitsch R., Bechmann I., Deisz R.A., Haas D., Lehmann T.N., Wendling U., et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356 (2000) 827-828
16. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7 (2001) 383-385
17. Secchiero P., Gonelli A., Carnevale E., Milani D., Pandolfi A., Zella D., et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107 (2003) 2250-2256
18. Secchiero P., Zerbinati C., Rimondi E., Corallini F., Milani D., Grill V., et al. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61 (2004) 1965-1974
19. Morel J., Audo R., Hahne M., and Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 280 (2005) 15709-15718
20. Ishimura N., Isomoto H., Bronk S.F., and Gores G.J. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 290 (2006) G129-G136
21. Ehrhardt H., Fulda S., Schmid I., Hiscott J., Debatin K.M., and Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22 (2003) 3842-3852
22. Baader E., Toloczko A., Fuchs U., Schmid I., Beltinger C., Ehrhardt H., et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res 65 (2005) 7888-7895
23. Hopkins-Donaldson S., Ziegler A., Kurtz S., Bigosch C., Kandioler D., Ludwig C., et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 10 (2003) 356-364
24. Shivapurkar N., Reddy J., Matta H., Sathyanarayana U.G., Huang C.X., Toyooka S., et al. Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene 21 (2002) 8510-8514
25. Liu X., Yue P., Zhou Z., Khuri F.R., and Sun S.Y. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 96 (2004) 1769-1780
26. Schneider P., Thome M., Burns K., Bodmer J.L., Hofmann K., Kataoka T., et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 7 (1997) 831-836
27. Schneider P., Bodmer J.L., Thome M., Hofmann K., Holler N., and Tschopp J. Characterization of two receptors for TRAIL. FEBS Lett 416 (1997) 329-334
28. Belyanskaya L.L., Hopkins-Donaldson S., Kurtz S., Simoes-Wust A.P., Yousefi S., Simon H.U., et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 117 (2005) 755-763
29. Olie R.A., Simoes-Wust A.P., Baumann B., Leech S.H., Fabbro D., Stahel R.A., et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60 (2000) 2805-2809
30. Secchiero P., Melloni E., Heikinheimo M., Mannisto S., Di Pietro R., Iacone A., et al. TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood 103 (2004) 517-522
31. Shivapurkar N., Toyooka S., Eby M.T., Huang C.X., Sathyanarayana U.G., Cunningham H.T., et al. Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther 1 (2002) 65-69
32. Shivapurkar N., Reddy J., Chaudhary P.M., and Gazdar A.F. Apoptosis and lung cancer: a review. J Cell Biochem 88 (2003) 885-898
33. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2 (2002) 420-430
34. Ishimura N., Isomoto H., Bronk S.F., and Gores G.J. TRAIL induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol (2005)
35. Koornstra J.J., Kleibeuker J.H., van Geelen C.M., Rijcken F.E., Hollema H., de Vries E.G., et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 200 (2003) 327-335
36. Tran S.E., Holmstrom T.H., Ahonen M., Kahari V.M., and Eriksson J.E. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem 276 (2001) 16484-16490
37. Hu W.H., Johnson H., and Shu H.B. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem 274 (1999) 30603-30610
38. Lin Y., Devin A., Cook A., Keane M.M., Kelliher M., Lipkowitz S., et al. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol 20 (2000) 6638-6645
39. Chaudhary P.M., Eby M., Jasmin A., Bookwalter A., Murray J., and Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7 (1997) 821-830
40. Budd R.C. Death receptors couple to both cell proliferation and apoptosis. J Clin Invest 109 (2002) 437-441
41. Kataoka T., Budd R.C., Holler N., Thome M., Martinon F., Irmler M., et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol 10 (2000) 640-648
42. Devin A., Lin Y., and Liu Z.G. The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases. EMBO Rep 4 (2003) 623-627
43. Sridhar S.S., Hedley D., and Siu L.L. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4 (2005) 677-685
44. Fulda S., Kufer M.U., Meyer E., van Valen F., Dockhorn-Dworniczak B., and Debatin K.M. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20 (2001) 5865-5877
45. De Ambrosis A., Casciano I., Croce M., Pagnan G., Radic L., Banelli B., et al. An interferon-sensitive response element is involved in constitutive caspase-8 gene expression in neuroblastoma cells. Int J Cancer 120 (2007) 39-47